Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec

First Posted Date: 2013-11-14

Last Posted Date: 2020-08-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 6163

Registration Number: NCT01984372

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: NNC0113-0987
Drug: placebo

First Posted Date: 2013-11-07

Last Posted Date: 2014-06-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 100

Registration Number: NCT01978613

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: lixisenatide

First Posted Date: 2013-10-31

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 404

Registration Number: NCT01973231

Locations: 🇬🇧
Novo Nordisk Investigational Site, Taunton, United Kingdom

A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency

Phase 1

Completed

Conditions: Growth Hormone Disorder
Growth Hormone Deficiency in Children

Interventions: Drug: somapacitan
Drug: somatropin

First Posted Date: 2013-10-31

Last Posted Date: 2020-12-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01973244

Locations: 🇨🇭
Novo Nordisk Investigational Site, Genève, Switzerland

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: NNC0113-0987
Drug: placebo

First Posted Date: 2013-10-23

Last Posted Date: 2014-06-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 82

Registration Number: NCT01967589

Project to Update the Study of Congenital Haemophilia in Spain

Completed

Conditions: Haemophilia A
Congenital Bleeding Disorder
Haemophilia B

Interventions: Other: No treatment given

First Posted Date: 2013-10-10

Last Posted Date: 2015-11-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1157

Registration Number: NCT01959555

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2013-10-10

Last Posted Date: 2019-07-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7637

Registration Number: NCT01959529

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wolverhampton, United Kingdom

A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri Lanka

Withdrawn

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2013-10-08

Last Posted Date: 2014-10-02

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT01957592

A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis
Inflammation

Interventions: Drug: NNC0215-0384
Drug: placebo

First Posted Date: 2013-10-07

Last Posted Date: 2014-10-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01955603

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/liraglutide
Drug: insulin glargine

First Posted Date: 2013-09-27

Last Posted Date: 2019-01-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 557

Registration Number: NCT01952145

Locations: 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy